

University of Parma Research Repository

Effects of intravenous romifidine, detomidine, detomidine combined with butorphanol, and xylazine on tear production in horses.

This is a pre print version of the following article:

Original

Effects of intravenous romifidine, detomidine, detomidine combined with butorphanol, and xylazine on tear production in horses / Leonardi, F.; Costa, G. L.; Dubau, M.; Sabbioni, A.; Simonazzi, B.; Angelone, M.. - In: EQUINE VETERINARY EDUCATION. - ISSN 0957-7734. - 32:S11(2020), pp. 53-57. [10.1111/eve.13040]

Availability: This version is available at: 11381/2854565 since: 2021-10-06T17:32:41Z

Publisher: Equine Veterinary Journal Ltd

Published DOI:10.1111/eve.13040

Terms of use:

Anyone can freely access the full text of works made available as "Open Access". Works made available

Publisher copyright

note finali coverpage

(Article begins on next page)

EFFECTS OF INTRAVENOUS ROMIFIDINE, DETOMIDINE, DETOMIDINE COMBINED WITH BUTORPHANOL, AND XYLAZINE ON TEAR PRODUCTION IN HORSES

1 **Running title:** effects of sedation on equine STT I values

2

```
3 Fabio Leonardi<sup>†*</sup>, Giovanna Lucrezia Costa<sup>‡</sup>, Morgane Dubau<sup>†</sup>, Alberto Sabbioni<sup>†</sup>, Barbara
```

4 Simonazzi^{\dagger}, Mario Angelone^{\dagger}

5

[†]Department of Veterinary Science, University of Parma, Italy

⁷ [‡]Department of veterinary Science, University of Messina, Italy

8 *Corresponding author: e-mail: <u>fabio.leonardi@unipr.it;</u> postal address: Department of

9 Veterinary Science, University of Parma, via del Taglio 10, 43126 Parma, Italy; phone

10 number: + 39 0521032779.

11 SUMMARY

Sedation facilitates the ocular examination in horses. Alpha2-adrenoceptor agonists are 12 commonly used in equine practice. If the eye is painful, the combination of an $\alpha 2$ -13 adrenoceptor agonist and butorphanol provides a greater analgesic effect. Unfortunately, little 14 is known about the effects of a2-adrenoceptor agonists on equine Schirmer tear test I (STT I) 15 values. The aim of the study was to assess the effects of intravenous romifidine, detomidine, 16 detomidine combined with butorphanol, and xylazine on the STT I values in horses. Forty 17 client-owned Italian saddle horses were enrolled. Horses received 0.04 mg/kg of romifidine 18 19 or 15 μ g/kg of detomidine or 10 μ g/kg of detomidine combined with 10 μ g/kg of butorphanol or 0.7 mg/kg of xylazine intravenously. The Schirmer tear test strip was inserted into the 20 21 lateral third side of the inferior conjunctival fornix for one minute in each eye. The STT I 22 measurements were performed before sedation and at 5, 15, 30, 60, 120 and 180 minutes after the administration of sedation. The data were analyzed by ANOVA. Romifidine did not 23 affect the STT I values. Detomidine significantly reduced the STT I values at 15 minutes 24 $(18.17 \pm 0.97 \text{ mm/min})$. The combination of detomidine and butorphanol significantly 25 reduced the STT I values at 30 and 60 minutes (17.44 \pm 0.99, 15.81 \pm 0.99 mm/min). 26 Xylazine significantly increased the STT I values at 5, 15 and 30 minutes (25.17 ± 0.99 , 27 26.72 ± 0.99 , 28.07 ± 0.99 mm/min). The STT I values at 180 minutes were similar to those 28 before sedation. These results suggest that the administration of xylazine or detomidine alone 29 30 or combined with butorphanol is associated with significant changes in aqueous tear production, whereas romifidine does not affect the STT I values. Romifidine is therefore 31 suitable for chemical restraint to measure tear production in horses. 32

33

34 Key words: horse, Schirmer tear test I, sedation, α2-adrenoceptor agonist, butorphanol

36 INTRODUCTION

The tear film confers the cornea an optical surface for the refraction of light, allows the mechanical removal of debris and bacteria, and lubricates the conjunctiva (Martin 2005). If a deficiency of the lacrimal system is supposed, the measurement of tear production is mandatory (Crispin 2000). The Schirmer tear test I (STT I) is the most commonly used test to measure the basal and reflex tear production in horses (Williams *et al.* 1979). Low STT I values than 10 mm/min are pathological, whereas high values are not pathological because horse's tear production may be as high as 35 mm/min (Hendrix 2005).

A single intravenous standard dose of an α 2-adrenoceptor agonist is commonly satisfactory to perform a complete ocular examination in horses (Hendrix 2005). If the eye is painful, the combination of an α 2-adrenoceptor agonist and butorphanol may be required to provide a greater analgesic effect (Hendrix 2005; Muir 2009; Bianchi *et al.* 2015).

Alpha2-adrenoceptor agonists induce a dose-dependent, rapid and quite predictable effect 48 (Muir 2009). Romifidine, detomidine and xylazine are the most commonly used α^2 -49 50 adrenoceptor agonists in equine practice (Nannarone et al. 2007). They vary in potency, duration of action, and side effects depending on α 2-adrenoceptor selectivity. Romifidine is 51 more potent than xylazine but it is less potent than detomidine (Muir 2009). Nevertheless, 52 0.04 mg/kg of romifidine appeared equipotent to 10 µg/kg of detomidine, whereas 0.08 53 mg/kg of romifidine appeared similar in potency to 1 mg/kg of xylazine (England et al. 54 55 1992).

The duration of action of detomidine is longer compared to that of xylazine but shortercompared to that of romifidine (Muir 2009).

58 With regard to side effects, the depression of cardiorespiratory function induced by xylazine 59 and romifidine is less marked than that caused by detomidine. Furthermore, romifidine and 60 detomidine induce less pronounced ataxia compared to that induced by xylazine (Muir 2009). Butorphanol is a κ -opioid receptor agonist and a μ -opioid receptor antagonist. It is not commonly used alone for an ocular examination because it may cause increased spontaneous movements. The combination of butorphanol and α 2-adrenoceptor agonist synergistically acts to improve sedative effects (Muir 2009).

Conflicting data about the effects of α2-adrenoceptor agonists on equine STT I values have
been previously reported. Intravenous administration of 20 µg/kg of detomidine or 150 mg of
xylazine significantly reduced the STT I values (Brightman *et al.* 1983; Ghaffari *et al.* 2017).
On the contrary, Marts *et al.* (1977) reported that xylazine had no demonstrable effect on tear
production in horses. To the authors' knowledge, there are no available data on the effects of
romifidine and detomidine combined with butorphanol on equine tear production.

The aims of the study were to evaluate the effects of intravenous romifidine, detomidine, detomidine combined with butorphanol, and xylazine on tear production as assessed with the STT I in horses and to evaluate the influence of the sex and right eye or left eye on the STT I values after sedation.

75

76 MATERIALS AND METHODS

77

78 Animals

This study was performed in accordance with the Legislative Decree n. 26 of 4th March 2014
under Italian Animal Welfare Legislation and was approved by the Institutional Ethics
Committee for animal welfare of the University of Parma. The owners signed a voluntary
informed consent form prior to the horses' enrollment.

The inclusion criteria were as follow: adult Italian saddle horses undergoing a radiologic or ultrasonographic assessment, no history of previous ocular disease, no drug therapy in the previous two months, and normal complete blood count and biochemical profile. The exclusion criteria were as follow: horses with abnormalities of the ocular surface or with
STT I values lower than 15 mm/min.

88

89 Schirmer tear test I measurements

An ocular examination consisting of a Schirmer tear test¹ and a slit lamp examination (SL-17²) was performed before sedation. The strip was inserted into the lateral third of the inferior conjunctival fornix for one minute in each eye. The STT I was performed first in the right eye.

The STT I readings were performed before sedation, at 5, 15, 30, 60, 120 and 180 minutes after the administration of sedation. The STT I measurements were performed in an enclosed space under the same conditions of light, temperature and relative humidity. The same experienced veterinarian blinded from the treatment performed the STT I measurements.

98

99 Sedation protocols

Food but not water was withheld for 12 hours prior to the administration of the sedation. Horses were randomly (simple randomization with the computer-generated random numbers) divided into four groups and were sedated with the corresponding drug intravenously. Horses belonged to the group R received 0.04 mg/kg of romifidine (Sedivet³). Patients of the group D were sedated with 15 μ g/kg of detomidine (Domosedan⁴). Animals of the group DB received 10 μ g/kg of detomidine combined with 10 μ g/kg of butorphanol (Nargesic⁵). Horses of the group X were sedated with 0.7 mg/kg of xylazine (Megaxilor⁶).

107

108 Data analysis

109 The data were analyzed with ANOVA by means of the general linear model (GLM)
110 procedure in SAS Version 9.4⁷. The fixed factors included sedation protocol (four levels:

romifidine, detomidine, detomidine combined with butorphanol, and xylazine), time (seven levels: before sedation, 5, 15, 30, 60, 120 and 180 minutes after the administration of sedation), sex (three levels: intact females, intact males, spayed males) and eye (two levels: right eye, left eye). The age (years) and weight (kg) of the horses were considered covariates. The STT I values were reported as least-squares means (LSMeans) \pm standard error of the mean (SEM). The age and weight were expressed as mean \pm standard deviation (SD). *P* values < 0.05 were considered significant.

118

119 **RESULTS**

Forty adult Italian saddle horses were included in the study. Each group consisted of 10subjects (Table 1). The STT I values are reported in table 2.

122 In the group R, there were no significant differences in the STT I values.

123 In the group D, the STT I value was significantly lower 15 minutes after the administration of

sedation compared to the values before sedation (P = 0.007), at 5 minutes (P = 0.001) and

125 180 minutes (
$$P = 0.001$$
).

126 In the group DB, the STT I value at 30 minutes was significantly lower compared to the

values before sedation (P = 0.004), at 120 minutes (P = 0.046) and 180 minutes (P = 0.046).

128 The STT I value at 60 minutes was significantly lower compared to the values before

sedation (P = 0.001), at 5 minutes (P = 0.006), 15 minutes (P = 0.024), 120 minutes (P = 0.024)

130 .001) and 180 minutes (P = 0.001).

In the group X, the STT I values at 5, 15 and 30 minutes were significantly higher compared to the value before sedation (P = 0.001). The STT I values at 5 and 15 minutes were significantly higher compared to those at 60 minutes ($P_5 = 0.029$, $P_{15} = 0.001$), 120 minutes ($P_5 = 0.013$, $P_{15} = 0.001$) and 180 minutes ($P_5 = 0.021$, $P_{15} = 0.001$). The STT I value at 30 minutes was significantly higher compared to those at 5 minutes (P = 0.038) and 120 minutes (P = 0.001).

137 With regard to sex and right eye and left eye, no significant differences were recorded.138

139 **DISCUSSION**

140 This study demonstrates that the administration of detomidine alone or combined with 141 butorphanol decreases tear production. Intravenous romifidine does not affect tear 142 production, whereas the administration of xylazine is associated with increased aqueous tear 143 production.

The choice of the most suitable α 2-adrenoceptor agonist for sedation is critical for the success 144 of the ocular examination (Hendrix 2005). Detomidine is often used because it ensures a 145 146 steady head position even though it is associated with decreased tear production (Ghaffari et al. 2017). As expected, decreased tear production was recorded 15 minutes after sedation 147 because the peak of the sedative effects of detomidine is reached within 15 minutes after 148 intravenous administration (Muir 2009). Nevertheless, differently from previous findings 149 (Ghaffari et al. 2017), the significant decrease in tear production is no longer present 30 150 minutes after sedation. Based on the dose-related effects of detomidine (Muir 2009), the 151 probable reason is that the dose employed in the present study is lower compared to that used 152 by Ghaffari et al. (2017). 153

154 One explanation for the decreased measurable tear production after the administration of 155 detomidine is the evaporative losses increased by inadequate blinking caused by sedation 156 (Crispin 2000).

157 Nevertheless, the most likely causes for the reduction in aqueous tear production are the 158 neurophysiological mechanism and hemodynamic changes. Even though specific details of 159 the innervation of equine lacrimal glands are poorly known (Crispin 2000), it is likely that the 160 postsynaptic activation of α 2-adrenoceptors in the central nervous system may have 161 decreased basal tear production. Furthermore, the reduction in the STT I values may be due 162 to the decrease in reflex tear production mediated by diminished nociceptive transmission, 163 which is modulated by α 2- adrenoceptors (Martin 2005).

With regard to hemodynamic changes, detomidine induces mild hypotension that is responsible for decreased perfusion of the lacrimal glands followed by a consequent decrease in the STT I values (Muir 2009). Detomidine could have additionally caused a direct vasoconstriction of the vessels of lacrimal glands.

168 Intravenous administration of the combination of detomidine and butorphanol is associated with a more accentuated and prolonged decrease in tear production compared to that induced 169 by detomidine alone. Furthermore, horses belonged to the group DB showed the lowest STT I 170 171 values recorded in the present study even though the STT I values do not go below the reference range reported in normal horses (Marts et al. 1997; Beech et al. 2003; Piccione et 172 al. 2008). These observations agree with those of similar studies in dogs (Dodam et al. 1998; 173 Sanchez et al. 2006) and underscore that opioidergic signalling pathways plays an important 174 role in tear production (Zagon et al. 2012). Moreover, it is likely that detomidine combined 175 with butorphanol may have additive and /or synergistic effects in decreasing equine tear 176 production improving analgesia and affecting hemodynamic changes and neurophysiological 177 mechanism (Muir 2009; Bianchi et al. 2015). 178

Another possible reason for the decreased measurable tear production caused by the combination of detomidine and butorphanol is a potential opioid-induced alteration of the metabolism of lacrimal glands (Mouney *et al.* 2011). Nevertheless, further studies are needed to clarify the effect of intravenous butorphanol alone on tear production.

An ocular examination is usually a short procedure and romifidine is not therefore the most
suitable α2-adrenoceptor agonist because its duration of action is longer compared to those of

185 detomidine and xylazine (Muir 2009). Furthermore, based on a previous study demonstrating that 0.04 mg/kg of romifidine reduced intraocular pressure in horses (Marzok et al. 2014), we 186 expected that the administration of romifidine was associated with decreased tear production. 187 188 Contradicting this expectation, romifidine did not affect the STT I measurements. The probable reason for these results is that the dose of romifidine employed in the present study 189 is too low to affect aqueous tear production. Even though α 2-adrenoceptor agonists 190 commonly induce hemodynamic changes in a dose-dependent manner (Nannarone et al. 191 2007), we supposed that 0.04 mg/kg of romifidine did not markedly reduce cardiac output in 192 193 horses enrolled in this study, as it could have certainly happened with higher doses (Peboni Figueiredo et al. 2005). Consequently, it is likely that a regular blood flow to lacrimal glands 194 195 was provided with no changes in the STT I values.

196 The effect of intravenous xylazine on tear production in horses has not been clearly identified. It seems that xylazine alone has no direct effects on tear production (Marts et al. 197 1977), whereas intravenous administration of 150 mg of xylazine is associated with 198 decreased tear production in anesthetized horses ranged in age from 6 months to 14 years 199 (Brightman et al. 1983). Unfortunately, Brightman et al. (1983) did not report the dose of 200 xylazine expressed as mg/kg. However, our results contradict previous findings because 201 intravenous xylazine unexpectedly increased the STT I values. There are no reports in the 202 veterinary literature that can explain our results. It is likely that the increased measurable tear 203 204 production was due to ataxia, excitation, movement and the head "jerks" caused by xylazine (Gilger et al. 2011). We suggest that this behavior may have increased complete blink rate 205 and, consequently, tear production (Crispin 2000). However, further studies are needed to 206 207 confirm this hypothesis.

With regard to the influence of sex and right or left eye on tear production, our results agree
with previous findings (Crispin 2000; Beech *et al.* 2003). In fact, in the present study, sex did

- not influence the STT I values (Beech *et al.* 2003) and the second eye was not affected by the
 stimulation of basal secretion in the first eye (Crispin 2000).
- The present study shows some limitations related to environmental conditions, equipotency of α 2-adrenoceptor agonists and head position.

The influence of time of day, season, and environment on tear production has not been entirely clarified by researchers (Beech *et al.* 2003; Piccione *et al.* 2008). These factors do not seem to influence the STT I values even though a circadian rhythm of tear production was reported (Beech *et al.* 2003; Piccione *et al.* 2008). In the present study, the influence of these variables on the STT I values was not investigated.

Another limitation of the study is that we did not accurately evaluate the equipotency of α 2adrenoceptor agonists. We chose approximate equipotent doses based on the veterinary literature (England *et al.* 1992; Nannarone *et al.* 2007).

Head position and height of the eye above the level of the heart affect intraocular pressure but no report investigated the influence of these variables on tear production (Holve 2012). Consequently, we cannot clearly exclude an influence of these factors on the STT I measurements.

In conclusion, intravenous administration of romifidine does not affect aqueous tear production and may be useful to measure tear production in horses undergoing ophthalmic procedures requiring sedation. Xylazine increases tear production and is not suitable for chemical restraint to perform a complete ocular examination in horses. The administration of detomidine alone or combined with butorphanol reduce the STT I values and the use of ophthalmic ointments is therefore recommended after sedation.

232

233 AUTHORS' DECLARATION OF INTERESTS

234 No conflicts of interest have been declared.

235

236 ETHICAL ANIMAL RESEARCH

This study was performed in accordance with the Legislative Decree n. 26 of 4th March 2014
under Italian Animal Welfare Legislation and was approved by the Institutional Ethics
Committee for animal welfare of the University of Parma.

240

241 ACKNOWLEDGEMENTS

The authors would like to remember Stefano Zanichelli, full professor of veterinary surgery who passed away on 9th December 2015. We really wish to thank him for, over the past years, working tirelessly to support scientific research.

245

246 AUTHORSHIP

F. Leonardi, B. Simonazzi, M. Dubau and M. Angelone designed the study. G.L. Costa and
A. Sabbioni undertook the statistical analyses. All authors contributed and commented to the
manuscript and read and approved the final version.

250

251 MANUFACTURERS' ADDRESSES

¹Schering Plough, Milan, Italy

²Kowa, Dusseldorf, Germany

- ³Boehringer Ingelheim Italia, Milan, Italy
- ⁴Orion Pharma, Milan, Italy
- ⁵Acme, Reggio Emilia, Italy
- ⁶Bio 98 Srl, Milan, Italy
- ⁷SAS Institute Inc., Cary, NC, USA

260 **REFERENCES**

- Beech, J., Zappala, R. A., Smith, G. and Lindborg, S. (2003) Schirmer tear test results in normal horses and ponies: effect of age, season, environment, sex, time of day and placement of strips. *Vet. Ophthalmol.* 6, 251–254.
- 264 2. Bianchi, E., Leonardi, F., Zanichelli, S., Sabbioni, A., Dondi, M., Natella, S. and
- Angelone M. (2015) Effect of Xylazine, Detomidine, and Detomidine–Butorphanol
- Combination on Latencies of Peaks I–V of Brainstem Auditory–Evoked Responses in
 Horses. J. Equine Vet. Sci. 35, 541-544.
- Brightman, A.H. 2nd, Manning, J.P., Benson, G.J. and Musselman, E.E. (1983)
 Decreased tear production associated with general anesthesia in the horse. *J. Am. Vet. Med. Ass.* 182, 243-244.
- Crispin, S.M. (2000) Tear-deficient and evaporative dry eye syndromes of the horse. *Vet. Ophthalmol.* 3, 87–92.
- 5. Dodam, J.R., Branson, K.R. and Martin, D.D. (1998) Effects of intramuscular sedative
 and opioid combinations on tear production in dogs. *Vet. Ophthalmol.* 1, 57-59.
- 275 6. England, G.C.W., Clarke, K.W. and Goossens, L. (1992) A comparison of the sedative
- effects of three α2-adrenoceptor agonists (romifidine, detomidine and xylazine) in the
 horse. *J. Vet. Pharmacol. Ther.* 15, 194-201.
- 278 7. Ghaffari, M.S., Brooks, D.E., Sabzevari, A., Ghamsari, S.M., Lakooraj, H.M. and Shad,
- H. (2017) Effects of intravenous detomidine on Schirmer tear test results in clinically
 normal horses. J. Equine Vet. Sci. 55, 97-99.
- 8. Gilger, B.C. and Stoppini, R. (2011) Equine Ocular Examination: Routine and Advanced
 Diagnostic Techniques. In: *Equine ophthalmology* 2nd edn., Ed: B.C. Gilger, Elsevier
- 283 Saunders, St. Louis, pp 1-48.

- 9. Hendrix, D.V.H. (2005) Eye examination techniques in horses. *Clin. Tech. Equine Pract.*4, 2-10.
- 10. Holve, D.L. (2012) Effect of sedation with detomidine on intraocular pressure with and
 without topical anesthesia in clinically normal horses. *J. Am. Vet. Med. Ass.*240, 308311.
- 11. Martin C.L. (2005) *Ophthalmic Disease in Veterinary Medicine*, Manson. London, pp
 219-222.
- 12. Marts, B.S., Bryan, G.M. and Prieur, D.J. (1977) Schirmer tear test measurement and
 lysozyme concentration of equine tears. *J. Equine Med. Surg.* 1, 427-430.
- 13. Marzok, M.A., El-khodery S.A. and Oheida, A.H. (2014) Effect of intravenous
 administration of romifidine on intraocular pressure in clinically normal horses. *Vet. Ophthalmol.* 17 (suppl. 1), 149-153.
- 14. Mouney, M.C., Accola, P.J., Cremer, J., Shepard, M.K., Rodriguez Guarin, C. and Hofmeister,
 E.H. (2011) Effects of acepromazine maleate or morphine on tear production before, during, and
 after sevoflurane anesthesia in dogs. *Am. J. Vet. Res.* 72, 1427-1430.
- 15. Muir, W.W. (2009) Anxiolytics, nonopioid sedative-analgesics, and opioid analgesics.
- In: *Equine anesthesia. Monitoring and emergency therapy*, 2nd edn., Ed: W.W. Muir and
- J.A.E. Hubbell, Elsevier Saunders, St. Louis, pp 185-209.
- 302 16. Nannarone, S., Gialletti, R., Veschini, I., Bufalari, A. and Moriconi, F. (2007) The Use
 303 of Alpha-2 Agonists in the Equine Practice: Comparison between Three Molecules. *Vet.*
- 304 *Res. Commun.* **31** (Suppl 1), 309-312.
- 17. Peboni Figueiredo, J., Muir, W.W., Smith, J. and Wolfrom, G.W. (2005) Sedative and
 Analgesic Effects of Romifidine in Horses. *Intern. J. Appl. Res. Vet. Med.* 3, 249-258.
- 18. Piccione, G., Giannetto, C., Fazio, F. and Giudice, E. (2008) Daily rhythm of tear
 production in normal horse. *Vet. Ophthalmol.* 11 (Suppl 1), 57–60.

309	19. Sanchez, R.F., Mellor, D. and Mould, J. (2006) Effects of medetomidine an
310	medetomidine-butorphanol combination on Schirmer tear test 1 readings in dogs. Ve
311	<i>Ophthalmol.</i> 9 , 33–37.

- 312 20. Williams, R.D., Manning, J.P. and Peiffer, R.L.Jr. (1979) The Schirmer tear test in the
- equine: normal values and the contribution of the gland of the nictitating membrane. J.
- 314 *Equine Med. Surg.* **3**, 117–119.
- 21. Zagon, I.S., Campbell, A.M., Sassani, J.W. and McLaughlin, P.J. (2012) Spontaneous
 episodic decreased tear secretion in rats is related to opioidergic signaling pathways.
- 317 Invest. Ophthalmol. Vis. Sci. 2012; **53**: 3234-3240.

319 TABLES

320

	Group R	Group D	Group DB	Group X	
	(n = 10)	(n = 10)	(n = 10)	(n = 10)	
Sex					
Number of intact females	6	3	2	6	
Number of intact males	2	3	3	2	
Number of spayed males	2	4	5	2	
Age (year)					
Mean ± standard deviation	23.3 ± 6.46	12.3 ± 7.64	15.8 ± 7.99	22.5 ± 6.45	
Range	15-33	3-22	3-33	15-33	
Body weight (kg)					
Mean ± standard deviation	492.5 ± 46.70	429.8 ± 54.32	500.8 ± 64.62	488 ± 36.80	
Range	426-574	351-506	394-608	430-570	

Table 1. Sex, age and body weight of horses belonged to the four groups

322 R = romifidine; D = detomidine; DB = detomidine combined with butorphanol; X = xylazine;

n = number of horses

Table 2. STT I values (mm/min) before sedation and at 5, 15, 30, 60, 120 and 180 minutes
after the administration of sedation in the four groups. STT I values are expressed as leastsquares means ± standard error of the mean (SEM)

	Before	5 min	15 min	30 min	60 min	120 min	180 min	SEM
	sedation							
Group R	24.18	24.23	25.18	24.83	23.33	22.88	23.93	1.00
Group D	21.48 ^b	20.79 ^a	18.17 ^{a,b,c}	20.17	19.33	20.44	22.51 ^c	0.975
Group DB	21.06 ^{a,c}	19.27 ^b	18.69 ^d	17.44 ^{c,f,n}	15.81 ^{a,b,d,e,r}	19.99 ^{n,r}	20.44 ^{e,f}	0.988
Group X	20.88 ^{a,b,c}	25.17 ^{a,d,f,h,}	ⁱ 26.72 ^{b,e,l,n}	ⁿ 28.07 ^{c,f,g}	22.13 ^{d,e}	21.73 ^{g,h,†}	¹ 21.93 ^{i,m}	0.999

328 R = romifidine; D = detomidine; DB = detomidine combined with butorphanol; X = xylazine;

329 min = minutes

330 In the same row, the same superscript (a,b,c,d,e,f,g,h,i,l,m,n,r) marks the values with a statistically

331 significant difference between them (P < 0.05).